Atara Biotherapeutics Inc (ATRA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have received an average recommendation of “Buy” from the ten brokerages that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $51.20.

A number of equities analysts recently issued reports on the company. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 24th. Mizuho restated a “buy” rating and issued a $62.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. BidaskClub cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 22nd. Finally, ValuEngine cut Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 12th.

Shares of ATRA stock opened at $38.34 on Wednesday. Atara Biotherapeutics has a 1 year low of $27.85 and a 1 year high of $54.45. The firm has a market cap of $1.77 billion, a PE ratio of -7.28 and a beta of 2.24.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.42). Sell-side analysts predict that Atara Biotherapeutics will post -5.99 earnings per share for the current year.

In related news, Director Joel S. Marcus sold 62,590 shares of Atara Biotherapeutics stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $36.07, for a total transaction of $2,257,621.30. Following the completion of the sale, the director now owns 32,590 shares of the company’s stock, valued at $1,175,521.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Joe Newell sold 1,500 shares of Atara Biotherapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $36.13, for a total value of $54,195.00. Following the sale, the insider now directly owns 48,646 shares of the company’s stock, valued at approximately $1,757,579.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 142,524 shares of company stock valued at $5,206,232. Insiders own 10.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC increased its stake in shares of Atara Biotherapeutics by 1.8% in the fourth quarter. FMR LLC now owns 5,274,169 shares of the biotechnology company’s stock worth $183,225,000 after purchasing an additional 93,432 shares during the period. Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 2.2% in the third quarter. Redmile Group LLC now owns 4,218,717 shares of the biotechnology company’s stock worth $174,444,000 after purchasing an additional 92,100 shares during the period. BlackRock Inc. increased its stake in shares of Atara Biotherapeutics by 0.6% in the fourth quarter. BlackRock Inc. now owns 3,513,235 shares of the biotechnology company’s stock worth $122,050,000 after purchasing an additional 22,453 shares during the period. Vanguard Group Inc. increased its stake in shares of Atara Biotherapeutics by 4.5% in the third quarter. Vanguard Group Inc. now owns 2,487,567 shares of the biotechnology company’s stock worth $102,861,000 after purchasing an additional 106,213 shares during the period. Finally, Vanguard Group Inc increased its stake in shares of Atara Biotherapeutics by 4.5% in the third quarter. Vanguard Group Inc now owns 2,487,567 shares of the biotechnology company’s stock worth $102,861,000 after purchasing an additional 106,213 shares during the period.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Return on Investment (ROI)

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.